Efficacy and safety of the combination of amlodipine 10/valsartan 160 in patients with hypertension and metabolic risk factors not controlled by the combination of ramipril 5/felodipine 5 - A subanalysis of the EXPRESS-C trial

被引：0
|
作者：
Trenkwalder, P.
Schaetzl, R.
Borbas, E.
Handrock, R.
Klebs, S.
机构：
[1] Starnberg Hosp, Starnberg, Germany
[2] Practice Gen Med, Grossheirath, Germany
[3] Practice Internal Med, Munster, Germany
[4] Novartis Pharma GmbH, Nurnberg, Germany
来源：
JOURNAL OF HYPERTENSION | 2007年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 38 条
  • [21] Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy
    Brachmann, Johannes
    Ansari, Anwar
    Mahla, Gerhard
    Handrock, Renate
    Klebs, Sven
    ADVANCES IN THERAPY, 2008, 25 (05) : 399 - 411
  • [22] Efficacy and tolerability of HCTZ 25 mg in combination with valsartan 160 mg in hypertensive patients not adequately controlled with a combination of high doses of ARBs and HCTZ 12,5 mg
    Girerd, X
    Denolle, T
    Brunel, P
    Yau, C
    Fiquet, B
    Moulin, B
    Herpin, D
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 107A - 108A
  • [23] A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160 mg versus valsartan/hydrochlorothiazide 160/12.5 mg in patients with essential hypertension uncontrolled by valsartan 160mg monotherapy
    Ahn, Youngkeun
    Kim, Yongcheol
    Chang, Kiyuk
    Kim, Weon
    Rhee, Moo-Yong
    Cha, Kwang Soo
    Hyon, Min Su
    Shim, Chi Young
    Lee, Sung Yun
    Kim, Doo Il
    Kim, Sang Wook
    Lim, Sang-Wook
    Han, Kyoo-Rok
    Jo, Sang-Ho
    Lee, Nae-Hee
    Kwan, Jun
    Ahn, Taehoon
    MEDICINE, 2018, 97 (37)
  • [24] Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
    Sohn, Il Suk
    Kim, Chong-Jin
    Oh, Byung-Hee
    Hong, Taek-Jong
    Park, Chang-Gyu
    Kim, Byung-Soo
    Chung, Woo-Baek
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2016, 16 (02) : 129 - 138
  • [25] The combination of amlodipine 5 mg and valsartan 160 mg lowers pulse pressure effectively and safely in elderly and non-elderly hypertensive patients not controlled by monotherapy with calcium channel blockers
    Brachmann, J.
    Handrock, R.
    Klebs, S.
    CIRCULATION, 2008, 118 (12) : E286 - E286
  • [26] Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: a randomized controlled trial
    Mangia, A
    Villani, MR
    Minerva, N
    Leandro, G
    Bacca, D
    Cela, M
    Carretta, V
    Attino, V
    Ventrella, F
    Giangaspero, A
    Andriulli, A
    JOURNAL OF HEPATOLOGY, 2001, 34 (03) : 441 - 446
  • [27] Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
    Il Suk Sohn
    Chong-Jin Kim
    Byung-Hee Oh
    Taek-Jong Hong
    Chang-Gyu Park
    Byung-Soo Kim
    Woo-Baek Chung
    American Journal of Cardiovascular Drugs, 2016, 16 : 139 - 139
  • [28] Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial
    Na, Sang-Hoon
    Lee, Hae-Young
    Baek, Sang Hong
    Jeon, Hui-Kyung
    Kang, Jin-Ho
    Kim, Yoon-Nyun
    Park, Chang-Gyu
    Ryu, Jae-Kean
    Rhee, Moo-Yong
    Kim, Moo-Hyun
    Hong, Taek-Jong
    Choi, Dong-Ju
    Cho, Seong-Wook
    Cha, Dong-Hun
    Jeon, Eun-Seok
    Kim, Jae-Joong
    Shin, Joon-Han
    Park, Sung-Ha
    Lee, Seung-Hwan
    John, Sung-Hee
    Shin, Eun-Seok
    Kim, Nam-Ho
    Lee, Sung-Yun
    Kwan, Jun
    Jeong, Myung-Ho
    Kim, Sang-Wook
    Jeong, Jin-Ok
    Kim, Dong-Woon
    Lee, Nam-Ho
    Park, Woo-Jung
    Ahn, Jeong-Cheon
    Won, Kyung-Heon
    Lee, Seung Uk
    Cho, Jang-Hyun
    Kim, Soon-Kil
    Ahn, Taehoon
    Hong, Sukkeun
    Yoo, Sang-Yong
    Kim, Song-Yi
    Kim, Byung-Soo
    Juhn, Jae-Hyeon
    Kim, Sun-Young
    Lee, Yu-Jeong
    Oh, Byung-Hee
    CLINICAL THERAPEUTICS, 2015, 37 (08) : 1726 - 1739
  • [29] Efficacy and safety of bisoprolol 5 mg plus amlodipine 5 mg in patients with hypertension uncontrolled on monotherapy with 5 mg of amlodipine, a phase III multicenter, randomized, double-blind, placebo-controlled clinical trial - the AMCOR study
    Jedrusik, Piotr
    Placha, Grzegorz
    Gaciong, Zbigniew
    AMCOR Trial Investigators
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (07) : 939 - 946
  • [30] Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial
    Cho, Eun Joo
    Kim, Moo Hyun
    Kim, Young-Hak
    Chang, Kiyuk
    Choi, Dong-Ju
    Kang, Woong Chol
    Shin, Jinho
    Kim, Seong Hwan
    Lee, Namho
    Son, Jang Won
    Doh, Joon-Hyung
    Kim, Woo-Shik
    Hong, Soon Jun
    Rhee, Moo-Yong
    Ahn, Youngkeun
    Lim, Sang-Wook
    Hong, Seung Pyo
    Choi, So-Yeon
    Hyon, Min Su
    Hwang, Jin-Yong
    Kwon, Kihwan
    Cha, Kwang Soo
    Ihm, Sang-Hyun
    Lee, Jae-Hwan
    Yoo, Byung-Su
    Kim, Hyo-Soo
    JOURNAL OF CLINICAL HYPERTENSION, 2023, 25 (09): : 817 - 827
1234